Inadequate treatment of congestive heart failure in dialysis patients.
Congestive heart failure (CHF) is highly prevalent in patients on renal replacement therapy and is a leading cause of death in such patients. Several studies suggest that therapeutic agents for the treatment of CHF, particularly angiotensin converting enzyme inhibitors and beta-blockers, are underused in end-stage renal disease patients with CHF. Although limited data are available, growing evidence suggests that therapeutic agents for CHF improve survival and are safe to use, assuming close monitoring of adverse events. The reluctance of physicians in prescribing these therapeutic agents and the reasons underlying the inconsistent use of these agents in the dialysis population need to be addressed.
Bouchard
Josée
J
Department of Medicine, Université de Montréal, and Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
Madore
François
F
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003956:Dialysis; D011307:Drug Prescriptions / Q000592:standards; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D017211:Treatment Failure
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors